Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03028246 · ClinicalTrials.gov registry record · NA

A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects

A NA study of Benign Centrally-Located Intracranial Tumors, sponsored by InSightec.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
2
Study locations

NCT03028246: Recruiting NA study of Benign Centrally-Located Intracranial Tumors, sponsored by InSightec.

NCT03028246 is a NA study of Benign Centrally-Located Intracranial Tumors that is actively recruiting participants, run by InSightec. The registered enrollment target is 20 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03028246, a NA study of Benign Centrally-Located Intracranial Tumors, is actively recruiting participants, sponsored by InSightec.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.

Interventions

  • DEVICE ExAblate 4000 System

Study Locations (2)

District of Columbia

  • Children's National Medical Center - Washington D.C.

Florida

  • Nicklaus Children's Hospital - Miami

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2017-02-28
Est. Completion 2026-12-31
Phase NA

Sponsor

InSightec

38 total trials

What the Registry Record Tells You About NCT03028246

The ClinicalTrials.gov registry entry for NCT03028246 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Benign Centrally-Located Intracranial Tumors appearing as the primary indexed condition, and to 1 intervention - of which ExAblate 4000 System is the first listed.

NCT03028246 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Florida.

Frequently Asked Questions

What is clinical trial NCT03028246 about?

NCT03028246 is a clinical study titled "A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects". The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of be...

What is the current status of trial NCT03028246?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2017-02-28. Estimated completion is 2026-12-31.

What conditions does trial NCT03028246 study?

This clinical trial studies the following conditions: Benign Centrally-Located Intracranial Tumors.

What interventions are being tested in trial NCT03028246?

The interventions under investigation include: ExAblate 4000 System (DEVICE).

Who is sponsoring clinical trial NCT03028246?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03028246 being conducted?

This trial has 2 study locations across District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.